Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: MCR004
MIFTS: 53

Macroglobulinemia

Categories: Immune diseases, Metabolic diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Macroglobulinemia

About this section

MalaCards integrated aliases for Macroglobulinemia:

Name: Macroglobulinemia 12 76 15
Waldenstrom Macroglobulinemia 73
Primary Macroglobulinemia 12

Classifications:

MalaCards categories:
Global: Metabolic diseases
Anatomical: Immune diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:9080
ICD10 33 C88.0
ICD9CM 35 273.3
MeSH 44 D008258
SNOMED-CT 68 35562000
Sources

Summaries for Macroglobulinemia

About this section
MalaCards based summary : Macroglobulinemia, also known as waldenstrom macroglobulinemia, is related to waldenstroem's macroglobulinemia and waldenstrom macroglobulinemia. An important gene associated with Macroglobulinemia is MYD88 (MYD88, Innate Immune Signal Transduction Adaptor), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Lenograstim and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 76 Macroglobulinemia is the presence of increased levels of macroglobulins in the circulating blood. It is... more...

Sources

Related Diseases for Macroglobulinemia

About this section

Diseases related to Macroglobulinemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 230)
# Related Disease Score Top Affiliating Genes
1 waldenstroem's macroglobulinemia 33.6 BTK CXCR4 MYD88
2 waldenstrom macroglobulinemia 33.0 BTK CD27 CD40LG CD70 CXCR4 ITGAE
3 monoclonal gammopathy of uncertain significance 32.3 IL6 MYD88
4 myeloma, multiple 30.3 CD27 CXCL12 CXCR4 IL6 TNFSF13B
5 cryoglobulinemia 30.3 CD27 CD40LG TNFSF13B
6 lymphocytic leukemia 30.3 BTK MYD88 PAX5
7 b-cell lymphomas 30.2 BTK PAX5 TNFRSF13C TNFSF13B
8 heavy chain disease 30.0 MYD88 PAX5
9 viral infectious disease 30.0 CD40LG CXCR4 IL6
10 primary agammaglobulinemia 29.8 TNFRSF13B TNFRSF13C
11 whim syndrome 29.7 CXCL12 CXCR4
12 immunoglobulin alpha deficiency 29.6 CD40LG TNFRSF13B
13 rheumatoid arthritis 29.5 CD40LG CXCL12 IL6 TNFSF13B
14 cryptococcal meningitis 29.4 TNFRSF13B TNFRSF13C TNFSF13B
15 autoimmune disease 29.1 CD40LG IL6 TNFRSF13B TNFRSF13C TNFSF13B
16 systemic lupus erythematosus 28.8 CD40LG CD70 IL6 TNFRSF13B TNFRSF13C TNFSF13B
17 lymphoma, non-hodgkin, familial 28.7 CD27 CD70 CXCL12 CXCR4 PAX5 TNFRSF13B
18 leukemia, chronic lymphocytic 28.7 CD27 CD40LG CD70 CXCL12 CXCR4 PAX5
19 macroglobulinemia, waldenstrom 1 12.3
20 macroglobulinemia, waldenstrom 2 12.1
21 schnitzler syndrome 11.5
22 light chain deposition disease 11.4
23 lymphoma 10.6
24 amyloidosis 10.3
25 leukemia 10.3
26 immunodeficiency with hyper-igm, type 4 10.2 CD40LG TNFSF13B
27 neuropathy 10.2
28 immunodeficiency with hyper-igm, type 1 10.2 BTK CD40LG
29 primary central nervous system lymphoma 10.2 MYD88 PAX5
30 intraocular lymphoma 10.2 CXCR4 PAX5
31 intussusception 10.2 CD40LG IL6
32 aids dementia complex 10.2 CXCL12 CXCR4
33 mesenteric lymphadenitis 10.2 IL6 MYD88
34 plasma protein metabolism disease 10.2 BTK CXCR4 MYD88
35 multicentric castleman disease 10.2 IL6 PAX5
36 hemorrhagic fever 10.1 CD40LG IL6
37 bacteriuria 10.1 CD40LG IL6
38 diffuse large b-cell lymphoma 10.1
39 hepatitis 10.1
40 toxoplasmosis 10.1 CD40LG IL6 MYD88
41 autoimmune disease of musculoskeletal system 10.1 CD40LG IL6 TNFSF13B
42 glomerulonephritis 10.1
43 hepatitis c 10.1
44 al amyloidosis 10.1
45 monoclonal paraproteinemia 10.1 CD27 MYD88
46 agammaglobulinemia, x-linked 10.1 BTK CD40LG CXCL12
47 connective tissue disease 10.1 CD40LG IL6 TNFSF13B
48 human immunodeficiency virus infectious disease 10.1 CXCL12 CXCR4 IL6
49 exanthema subitum 10.1 CD40LG IL6
50 immunoglobulin a deficiency 1 10.1 BTK CD40LG TNFRSF13B

Graphical network of the top 20 diseases related to Macroglobulinemia:



Diseases related to Macroglobulinemia
Sources

Symptoms & Phenotypes for Macroglobulinemia

About this section

GenomeRNAi Phenotypes related to Macroglobulinemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.32 CD40LG CD70 CXCR4 MYD88
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.32 BTK CD27 CD40LG CD70 CXCR4 MYD88

MGI Mouse Phenotypes related to Macroglobulinemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10 BTK CD27 CD40LG CD70 CXCL12 CXCR4
2 immune system MP:0005387 9.8 BTK CD27 CD40LG CD70 CXCL12 CXCR4
3 neoplasm MP:0002006 9.1 BTK CXCR4 IL6 MYD88 PAX5 TNFRSF13B
Sources

Drugs & Therapeutics for Macroglobulinemia

About this section

Drugs for Macroglobulinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 379)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 135968-09-1
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 1177-87-3
5
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
6
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 179324-69-7 387447 93860
7
Cytarabine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 147-94-4 6253
8
Etoposide Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
9
Methotrexate Approved Phase 4,Phase 2,Phase 1,Not Applicable 59-05-2, 1959-05-2 126941
10
leucovorin Approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
11
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 52-24-4 5453
12
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
13
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
14
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
15
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
16
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
18
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2920-86-7
19 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
24 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
26 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
27 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
29 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
30 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1
32 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
33 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1
35 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
36 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
37 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Etoposide phosphate Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
39 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 1
41 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 1
43 Immunoglobulins Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Vitamin B Complex Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Folic Acid Antagonists Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Protective Agents Phase 4,Phase 2,Phase 1,Not Applicable
48 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Antibodies Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 478)
# Name Status NCT ID Phase Drugs
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia Recruiting NCT02844322 Phase 4 Bortezomib;Rituximab
3 Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia Recruiting NCT02844361 Phase 4
4 The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM Recruiting NCT02844309 Phase 4 Thalidomide
5 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
6 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
7 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
8 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
9 Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia Completed NCT00566332 Phase 3 Chlorambucil;Fludarabine
10 Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma Completed NCT00608374 Phase 3 chlorambucil;fludarabine phosphate
11 A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab Completed NCT01461928 Phase 3 Chemotherapy (Induction Period);Rituximab
12 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
13 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
14 Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation Completed NCT00031668 Phase 3
15 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
16 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
17 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
18 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
19 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
20 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
21 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
22 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
23 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
24 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3
25 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
26 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
27 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
28 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
29 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. Completed NCT00801281 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2
30 Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia Recruiting NCT01788020 Phase 3 Dexamethasone, Rituximab, Cyclophosphamide;Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
31 Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Recruiting NCT02991638 Phase 3 Ibrutinib
32 Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) Recruiting NCT02626455 Phase 3 Copanlisib (BAY80-6946);Placebo;Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Bendamustine;Prednisone
33 Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia Active, not recruiting NCT02165397 Phase 3 Ibrutinib;Placebo;Rituximab
34 A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM) Active, not recruiting NCT03053440 Phase 3 BGB-3111;Ibrutinib
35 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
36 Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated NCT01732926 Phase 3 Idelalisib;Rituximab;Bendamustine;Placebo
37 Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated NCT01732913 Phase 3 Placebo;Rituximab;Idelalisib
38 A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia Unknown status NCT01142011 Phase 2 Belimumab
39 Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia Unknown status NCT01046006 Phase 2 Bortezomib, Rituximab, Dexamethasone
40 Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia Unknown status NCT00041379 Phase 1, Phase 2 beta alethine
41 PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia Unknown status NCT02971982 Phase 1, Phase 2 rituximab /Dexamethasone/cyclophosphamide;Velcade/Dexamethasone/cyclophosphamide
42 A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 Unknown status NCT01813227 Phase 2 Carfilzomib;Rituximab;Dexamethasone
43 Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients Unknown status NCT02566265 Phase 2
44 Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas Unknown status NCT00783367 Phase 2 lenalidomide-low dose dexamethasone plus rituximab;Lenalidomide + Rituximab
45 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
46 Comparison of Fludarabine Plus Total-Body Irradiation With Combination Chemotherapy Followed by Donor Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Unknown status NCT00041288 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;methotrexate;mycophenolate mofetil;tacrolimus
47 Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma Unknown status NCT00937183 Phase 1, Phase 2
48 Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers Unknown status NCT00003163 Phase 2 cyclophosphamide;melphalan
49 Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma Unknown status NCT00397800 Phase 1, Phase 2 cyclophosphamide;fludarabine phosphate
50 Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia Unknown status NCT01016990 Phase 2 valproic acid

Search NIH Clinical Center for Macroglobulinemia

Inferred drug relations via UMLS 73 / NDF-RT 51 :
Sources

Genetic Tests for Macroglobulinemia

About this section
Sources

Anatomical Context for Macroglobulinemia

About this section

MalaCards organs/tissues related to Macroglobulinemia:

41
B Cells, Bone, Bone Marrow, T Cells, Liver, Spleen, Myeloid
Sources

Publications for Macroglobulinemia

About this section

Articles related to Macroglobulinemia:

(show top 50) (show all 1094)
# Title Authors Year
1
A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with WaldenstrAPm macroglobulinemia. ( 29869556 )
2018
2
Idelalisib in a patient with refractory WaldenstrAPm's macroglobulinemia complicated by anuric renal failure: a case report. ( 29890999 )
2018
3
Fifty-Year Incidence of WaldenstrAPm Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review. ( 29656787 )
2018
4
Waldenstrom's Macroglobulinemia: An Update. ( 29326801 )
2018
5
Non-myeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory WaldenstrAPm macroglobulinemia: evidence for a graft-<i>versus</i>-lymphoma effect. ( 29545343 )
2018
6
[<sup>18</sup>F]Florbetaben PET-CT confirms AL amyloidosis in a patient with WaldenstrAPm's Macroglobulinemia. ( 29650640 )
2018
7
Chronic diarrhea: A case of WaldenstrAPm Macroglobulinemia. ( 29463427 )
2018
8
Fitting mSMART Into the Current Clinical Management of WaldenstrAPm Macroglobulinemia. ( 29392274 )
2018
9
Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With WaldenstrAPm Macroglobulinemia. ( 29685422 )
2018
10
MYD88 mutation status does not impact overall survival in WaldenstrAPm macroglobulinemia. ( 29080258 )
2018
11
A rare neurological complication of Waldenstrom's Macroglobulinemia. ( 29113857 )
2018
12
Cardiopulmonary Bypass in the Setting of WaldenstrAPm's Macroglobulinemia. ( 29921992 )
2018
13
Ibrutinib withdrawal symptoms in patients with WaldenstrAPm macroglobulinemia. ( 29472352 )
2018
14
WaldenstrAPm macroglobulinemia treatment algorithm 2018. ( 29712895 )
2018
15
Waldenstrom macroglobulinemia involving the superior rectus muscle. ( 29780960 )
2018
16
Imaging spectrum of Bing-Neel syndrome: how can a radiologist recognise this rare neurological complication of WaldenstrAPm's macroglobulinemia? ( 29922935 )
2018
17
A safety profile of medications used to treat WaldenstrAPm's macroglobulinemia. ( 29768934 )
2018
18
Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for WaldenstrAPm Macroglobulinemia. ( 29439186 )
2018
19
Chemokine Receptor CXCR4-Targeted PET/CT With 68Ga-Pentixafor Shows Superiority to 18F-FDG in a Patient With WaldenstrAPm Macroglobulinemia. ( 29742593 )
2018
20
Impact of ibrutinib dose intensity on patient outcomes in previously treated WaldenstrAPm macroglobulinemia. ( 29773590 )
2018
21
Kidney Involvement of Patients with WaldenstrAPm Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders. ( 29848505 )
2018
22
Calorimetric markers for monitoring of multiple myeloma and WaldenstrAPm's macroglobulinemia patients. ( 29362827 )
2018
23
WaldenstrAPm macroglobulinemia presenting as cryoglobulinemic type II membranoproliferative glomerulonephritis. ( 29571917 )
2018
24
Duodenal Scalloping Diagnoses WaldenstrAPm Macroglobulinemia. ( 29660526 )
2018
25
Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series. ( 28583038 )
2018
26
Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in WaldenstrAPm Macroglobulinemia. ( 29661775 )
2018
27
Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom's macroglobulinemia. ( 29218718 )
2018
28
Lung consolidation as a rare presentation of lymphoplasmacytic lymphoma with extramedullary WaldenstrAPm's macroglobulinemia. ( 29686791 )
2018
29
Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic WaldenstrAPm Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent. ( 29963517 )
2018
30
Spotting the elusive Siberian tiger: Complete response to ibrutinib in a patient with WaldenstrAPm Macroglobulinemia. ( 29756293 )
2018
31
Highly sensitive <i>MYD88</i><sup>L265P</sup> mutation detection by droplet digital polymerase chain reaction in WaldenstrAPm macroglobulinemia. ( 29567768 )
2018
32
True, true unrelated? Coexistence of Waldenstrom's macroglobulinemia and cardiac transthyretin Amyloidosis. ( 29674499 )
2018
33
Intensely Pruritic Papules and Plaques in Waldenstrom's Macroglobulinemia. ( 29386839 )
2018
34
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with WaldenstrAPm macroglobulinemia. ( 29610969 )
2018
35
Phase 3 Trial of Ibrutinib plus Rituximab in WaldenstrAPm's Macroglobulinemia. ( 29856685 )
2018
36
Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. ( 30315235 )
2018
37
Gene Expression Profile Signature of Aggressive Waldenström Macroglobulinemia with Chromosome 6q Deletion. ( 30402490 )
2018
38
Cutaneous macroglobulinosis as the initial presentation of Waldenström macroglobulinemia in a patient with a history of diffuse large B-cell lymphoma. ( 30073689 )
2018
39
High-Dose Therapy and Hematopoietic Stem Cell Transplantation in Waldenström Macroglobulinemia. ( 30190024 )
2018
40
A Case of Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma With Lung Lesion. ( 30239460 )
2018
41
Prognostic factors and primary treatment for Waldenström macroglobulinemia - a Swedish Lymphoma Registry study. ( 30198549 )
2018
42
Beneficial Effect of Bendamustine in a Patient with Anti-MAG/SGPG Neuropathy and Bing-Neel Syndrome Associated with Waldenström Macroglobulinemia: A Case Report. ( 29983700 )
2018
43
Stiff-person Syndrome with Waldenström Macroglobulinemia. ( 29984750 )
2018
44
Ibrutinib in the management of Waldenstrom macroglobulinemia. ( 29996737 )
2018
45
Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. ( 30044692 )
2018
46
Distal Tibia and Foot Involvement in a Patient With Waldenstrom's Macroglobulinemia. ( 30048579 )
2018
47
Selecting Initial Therapy for Newly Diagnosed Waldenström Macroglobulinemia. ( 30052482 )
2018
48
Pulmonary extranodal marginal zone lymphoma that presented with macroglobulinemia and marked plasmacytic cell proliferation carrying the t(14;18)(q32;q21)/MALT1-immunoglobulin heavy-chain fusion gene in pleural fluid. ( 30089750 )
2018
49
Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia. ( 30104397 )
2018
50
Agranulocytosis Associated with Waldenström Macroglobulinemia. ( 30114687 )
2018
Sources

Variations for Macroglobulinemia

About this section
Sources

Expression for Macroglobulinemia

About this section
Search GEO for disease gene expression data for Macroglobulinemia.
Sources

Pathways for Macroglobulinemia

About this section

Pathways related to Macroglobulinemia according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.88 BTK CD27 CD40LG CD70 IL6 MYD88
2
ERK Signaling 64
Show member pathways
 13.72 BTK CD27 CD40LG CD70 CXCL12 CXCR4
3
PEDF Induced Signaling 64
Show member pathways
 13.58 BTK CD27 CD40LG CD70 CXCL12 CXCR4
4
TGF-Beta Pathway 64
Show member pathways
 13.4 BTK CXCL12 CXCR4 IL6 ITGAE TNFRSF13C
5
Cytokine Signaling in Immune system 66
Show member pathways
 13.27 CD27 CD40LG CD70 IL6 MYD88 TNFRSF13B
6
PAK Pathway 64
Show member pathways
 13.09 BTK CD27 CD40LG CD70 CXCL12 CXCR4
7
Allograft rejection 1 37
Show member pathways
 12.81 CD40LG CXCL12 CXCR4 IL6 TNFRSF13B TNFRSF13C
8
Development Angiotensin activation of ERK 22
Show member pathways
 12.67 BTK CD27 CD40LG CD70 CXCL12 CXCR4
9
NF-KappaB Family Pathway 64
Show member pathways
 12.64 CD40LG CXCL12 IL6 MYD88 TNFRSF13C TNFSF13B
10
Akt Signaling 64
Show member pathways
 12.55 BTK CD27 CD40LG CD70 CXCL12 CXCR4
11
4-1BB Pathway 64
Show member pathways
 12.53 CD27 CD40LG CD70 CXCR4
12
NF-kappaB Signaling 4
12.46 BTK CD40LG CXCL12 CXCR4 MYD88 PAX5
13
TRAF Pathway 64
Show member pathways
 12.29 BTK CD27 CD40LG CD70 MYD88 TNFRSF13B
14
Epstein-Barr virus infection 37
12.13 BTK IL6 MYD88
15
G-protein signaling Regulation of p38 and JNK signaling mediated by G-proteins 22
Show member pathways
 12.11 BTK CXCL12 CXCR4 ITGAE MYD88
16
Diseases associated with the TLR signaling cascade 66
Show member pathways
 12.1 BTK IL6 MYD88
17
C-type lectin receptor signaling pathway 37
Show member pathways
 12.05 BTK IL6 MYD88
18
Immune response IFN gamma signaling pathway 22
Show member pathways
 11.99 BTK CXCL12 IL6 TNFRSF13C TNFSF13B
19
Jak-Stat Signaling Pathway (sino) 67
11.74 CXCL12 CXCR4 IL6
20
Rheumatoid arthritis 37
11.74 CXCL12 IL6 TNFSF13B
21
Apoptosis and survival Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway 22
Show member pathways
 11.64 CD40LG TNFRSF13B TNFSF13B
22
T Cell Co-Signaling Pathway: Ligand-Receptor Interactions 65
11.53 CD27 CD40LG CD70
23
B Cell Development Pathways 65
11.49 CD27 CD40LG CXCR4 PAX5 TNFRSF13B
24
Malaria 37
11.45 CD40LG IL6 MYD88
25
NF-kappa B signaling pathway 37
11.41 BTK CD40LG CXCL12 MYD88 TNFRSF13C TNFSF13B
26
Primary immunodeficiency 37
11.35 BTK CD40LG TNFRSF13B TNFRSF13C
27
Syndecan-4-mediated signaling events 1
11.23 CXCL12 CXCR4 TNFRSF13B
28
TNFs bind their physiological receptors 66
11.23 CD27 CD70 TNFRSF13B TNFSF13B
29
G-protein signaling_RhoB regulation pathway 22
11.14 BTK CD40LG CD70 CXCL12 IL6 TNFSF13B
30
G-protein signaling_Rap2B regulation pathway 22
10.94 BTK CD40LG CD70 CXCL12 IL6 ITGAE
Sources

GO Terms for Macroglobulinemia

About this section

Cellular components related to Macroglobulinemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.7 BTK CD27 CD40LG CD70 CXCL12 CXCR4
2 external side of plasma membrane GO:0009897 9.1 CD27 CD40LG CXCL12 CXCR4 ITGAE TNFRSF13C

Biological processes related to Macroglobulinemia according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.91 BTK MYD88 TNFRSF13B TNFRSF13C TNFSF13B
2 inflammatory response GO:0006954 9.87 CD40LG CXCR4 IL6 MYD88
3 regulation of signaling receptor activity GO:0010469 9.85 CD40LG CD70 CXCL12 IL6 TNFSF13B
4 response to virus GO:0009615 9.72 CXCL12 CXCR4 MYD88
5 T cell costimulation GO:0031295 9.65 CD40LG TNFRSF13C TNFSF13B
6 immune response GO:0006955 9.63 CD40LG CD70 CXCL12 CXCR4 IL6 TNFSF13B
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.62 BTK CD40LG IL6 MYD88
8 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.58 BTK MYD88
9 negative regulation of B cell proliferation GO:0030889 9.56 BTK TNFRSF13B
10 immunoglobulin mediated immune response GO:0016064 9.54 CD27 MYD88
11 positive regulation of B cell differentiation GO:0045579 9.52 BTK CD27
12 response to peptidoglycan GO:0032494 9.49 IL6 MYD88
13 immunoglobulin secretion GO:0048305 9.43 CD40LG TNFSF13B
14 B cell homeostasis GO:0001782 9.43 TNFRSF13B TNFRSF13C TNFSF13B
15 B cell costimulation GO:0031296 9.4 TNFRSF13C TNFSF13B
16 positive regulation of germinal center formation GO:0002636 9.37 TNFRSF13C TNFSF13B
17 positive regulation of T cell proliferation GO:0042102 9.26 CD40LG IL6 TNFRSF13C TNFSF13B
18 tumor necrosis factor-mediated signaling pathway GO:0033209 9.1 CD27 CD40LG CD70 TNFRSF13B TNFRSF13C TNFSF13B

Molecular functions related to Macroglobulinemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.46 CD70 CXCL12 MYD88 TNFSF13B
2 tumor necrosis factor receptor binding GO:0005164 9.13 CD40LG CD70 TNFSF13B
3 cytokine activity GO:0005125 9.02 CD40LG CD70 CXCL12 IL6 TNFSF13B
Sources

Sources for Macroglobulinemia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....